A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: brentuximab vedotin
DRUG: cyclophosphamide
DRUG: doxorubicin
DRUG: prednisone

Sponsor

Seagen, a wholly owned subsidiary of Pfizer